文献速递冠心病

新型即时肌钙蛋白检测单次排除急性心肌梗死的有效性

Validity of a Novel Point-of-Care Troponin Assay for Single-Test Rule-Out of Acute Myocardial Infarction.
PubMed 文献 · JAMA Cardiol · 2018-01-01

本研究在单个城市区域急诊科纳入354例疑似急性心肌梗死患者,比较新型即时肌钙蛋白I检测(i-STAT TnI-Nx,15分钟出结果)与高敏肌钙蛋白I检测的判别能力。结果显示两种检测的AUC无显著差异,TnI-Nx低于11 ng/L可识别56.7%低危患者,敏感性及阴性预测值均为100%。

要点

  • 新型即时肌钙蛋白检测15分钟出结果,判别能力与高敏肌钙蛋白检测相当。
  • TnI-Nx低于11 ng/L可安全识别56.7%低危患者,敏感性100%。
  • 该检测可能加速急诊决策并促进低危患者安全离院。

核心结论

  • 新型即时肌钙蛋白检测单次采血排除急性心肌梗死的判别能力与高敏肌钙蛋白I检测相当。

研究设计与样本

  • 观察性研究,在单个城市区域急诊科纳入354例疑似急性心肌梗死的成人患者。

主要发现

  • TnI-Nx低于11 ng/L识别201例(56.7%)低危患者,敏感性100%(95% CI,93.7%-100%),阴性预测值100%(95% CI,98.2%-100%)。
  • hs-cTnI低于3 ng/L识别154例(43.5%)低危患者,敏感性100%(95% CI,93.7%-100%),阴性预测值100%(95% CI,97.6%-100%)。

关键数值与推荐

  • TnI-Nx检测阈值低于11 ng/L用于单次排除急性心肌梗死,敏感性100%,阴性预测值100%。
  • hs-cTnI检测阈值低于3 ng/L用于单次排除急性心肌梗死,敏感性100%,阴性预测值100%。

临床怎么用

  • 急诊科可采用新型即时肌钙蛋白检测15分钟出结果,单次低于11 ng/L可快速识别低危患者并考虑安全离院。

局限性

  • 研究为单中心观察性设计,样本量354例,外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Emergency department (ED) investigations of patients with suspected acute myocardial infarction (AMI) are time consuming, partly because of the turnaround time of laboratory tests. Current point-of-care troponin assays shorten test turnaround times but lack precision at lower concentrations. Development of point-of-care troponin assays with greater analytical precision could reduce the decision-making time in EDs for ruling out AMI. OBJECTIVE: To determine the clinical accuracy for AMI of a single troponin concentration measured on arrival to ED with a new-generation, higher precision point-of-care assay with a 15-minute turnaround time. DESIGN, SETTING, AND PARTICIPANTS: This observational study occurred at a single urban regional ED. Adults presenting acutely from the community to the ED with symptoms suggestive of AMI were included. Troponin concentrations were measured on ED arrival with both a novel point-of-care assay (i-STAT TnI-Nx; Abbott Point of Care) and a high-sensitivity troponin I assay (Architect hs-cTnI; Abbott Diagnostics). MAIN OUTCOMES AND MEASURES: The primary outcome was type 1 AMI during index presentation. We compared the discrimination ability of the TnI-Nx assay with the hs-cTnI assay using the area under receiver operator characteristic curve (AUC) and sensitivity, negative predictive value, and the proportion of negative test results at thresholds with 100% sensitivity. RESULTS: Of 354 patients (255 [72.0%] men; mean [SD] age, 62 [12] years), 57 (16.1%) experienced an AMI. Eighty-five patients (24.0%) presented to the ED less than 3 hours after symptom onset. No difference was found between the AUC of the TnI-Nx assay (0.975 [95% CI, 0.958-0.993]) and the hs-cTnI assay (0.970 [95% CI, 0.949 to 0.990]; P = .46). A TnI-Nx assay result of less than 11 ng/L identified 201 patients (56.7%) as low risk, with a sensitivity of 100% (95% CI, 93.7%-100%) and a negative predictive value of 100% (95% CI, 98.2%-100%). In comparison, an hs-cTnI assay result of less than 3 ng/L identified 154 patients (43.5%) as low risk, with a sensitivity of 100% (95% CI, 93.7%-100%) and a negative predictive value of 100% (95% CI, 97.6%-100%). CONCLUSIONS AND RELEVANCE: A novel point-of-care troponin assay that can produce a result 15 minutes after blood sampling had comparable discrimination ability to an hs-cTnI assay for ruling out AMI after a single blood test. Use in the ED may facilitate earlier decision making and could expedite the safe discharge of a large proportion of low-risk patients.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Pickering JW, Young JM, George PM, et al. Validity of a Novel Point-of-Care Troponin Assay for Single-Test Rule-Out of Acute Myocardial Infarction. JAMA Cardiol. 2018. PMID: 30347004. doi:10.1001/jamacardio.2018.3368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。